|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2024
Anzahl der Publikationen: 1
2024
Fischer, Luca 
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]